<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865111</url>
  </required_header>
  <id_info>
    <org_study_id>06-0646-001</org_study_id>
    <nct_id>NCT00865111</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions</brief_title>
  <official_title>A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Sustained Release Tablets in Fasted, Normal, Healthy Men.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion&#xD;
      150 mg sustained release tablet to that of Wellbutrin SR sustained release tablet after a&#xD;
      single, one-tablet dose in fasted subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.&#xD;
&#xD;
      Official Title: A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study&#xD;
      of Bupropion Sustained Release Tablets in Fasted, Normal, Healthy Men.&#xD;
&#xD;
      Further study details as provided by Actavis Elizabeth LLC:&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Rate and Extend of Absorption&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>120 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupropion 150 mg Extended-Released Tablet, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion 150 mg Extended-Released Tablet, single dose</intervention_name>
    <description>A: Experimental Subjects received Abrika formulated products under fasting conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Bupropion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose</intervention_name>
    <description>B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Bupropion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is the individual a healthy, normal adult man who volunteers to participate?&#xD;
&#xD;
          -  Is he 18-45 years of age, inclusive?&#xD;
&#xD;
          -  Is his BMI between 19 and 30, inclusive?&#xD;
&#xD;
          -  Is he considered reliable and capable of understanding his responsibility and role in&#xD;
             the study?&#xD;
&#xD;
          -  Has he provided written informed consent? A no answer to any of the above questions&#xD;
             indicates that the individual is ineligible for enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does the individual have a history of allergy or hypersensitivity to bupropion?&#xD;
&#xD;
          -  Does he have clinically significant laboratory abnormalities that would interfere with&#xD;
             the conduct or interpretation of the study or jeopardize his safety?&#xD;
&#xD;
          -  Does he have significant history or clinical evidence of auto-immune, cardiovascular,&#xD;
             gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing&#xD;
             infection, pancreatic, renal or other diseases, conditions or surgeries that would&#xD;
             interfere with the conduct or interpretation of the study or jeopardize his/her&#xD;
             safety?&#xD;
&#xD;
          -  Does he have serious psychological illness?&#xD;
&#xD;
          -  Does he have significant history (within the past year) or clinical evidence of&#xD;
             alcohol or drug abuse?&#xD;
&#xD;
          -  Does he have a positive urine drug screen or saliva alcohol screen, or a positive&#xD;
             HIV-l, or hepatitis B or C screen?&#xD;
&#xD;
          -  Has he consumed grapefruit or grapefruit juice during the 7-day period preceding study&#xD;
             initiation?&#xD;
&#xD;
          -  Is he unable to refrain from the use of alcohol or xanthine-containing foods or&#xD;
             beverages during periods beginning 48 hours prior to study drug administration and&#xD;
             ending when the last blood sample has been taken in each study period?&#xD;
&#xD;
          -  Has he used any prescription drug during the 14-day period prior to study initiation,&#xD;
             or any OTC drug during the 72-hour period preceding study initiation?&#xD;
&#xD;
          -  Is he unable to refrain from the use of all concomitant medications during the study?&#xD;
&#xD;
          -  Has he donated or lost blood, or participated in a clinical study which involved the&#xD;
             withdrawal of a large volume of blood (480 mL or more), during the six week period&#xD;
             preceding study initiation?&#xD;
&#xD;
          -  Has he donated plasma during the two week period preceding study initiation?&#xD;
&#xD;
          -  Has he received an investigational drug during the 30 day period preceding study&#xD;
             initiation?&#xD;
&#xD;
          -  Is he a heavy smoker (usually smoking more than 25 cigarettes per day? A yes answer to&#xD;
             any of the above questions indicates that the individual is ineligible for enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio R. Pizarro,, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Ft. Myers, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Ft. Myers, Inc.</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

